GeneMatrix Promotes Sex and Respiratory Infection Testing Products at MEDLAB

GeneMatrix (Seoul, South Korea) promoted its main NeoPlex family of sex and respiratory infection testing products, at MEDLAB Middle East, which took place from 3-6 February 2020 at the Dubai World Trade Centre. MEDLAB Middle East, the Middle East & North Africa (MENA) region’s largest medical laboratory exhibition and congress, drew over 25,800 medical laboratory industry professionals and 600 exhibitors from 35 countries.

GeneMatrix focuses on leading the personalized medicine business through the development of competitive platforms and molecular diagnosis products. GeneMatrix’s proprietary RFMP platform technology can derive values from the genetic information of living creatures. The RFMP technology embodies unparalleled specifications for precision, sensitivity, digitalized quantitative analysis, multi-biomarker’s batch analysis and large quantity sample processing. The elements of biotechnology, nanotechnology and IT technology are organically fused in RFMP technology, and it is now being widely used. Its utilization will be extended to early diagnosis, prognosis determination, selection of therapeutic agent, treatment reaction monitoring for chronic intractable diseases including infectious, metabolic, neoplastic and genetic diseases.


At MEDLAB Middle East 2020, promoted sex and respiratory infection testing products of its main pipeline, NeoPlex, which are based om the company's original C-Tag technology. GeneMatrix offers multiple products in its respiratory testing line. In the respiratory virus panel line, it has developed NeoPlex RV-Panel A and NeoPlex RV-Panel B, while in the bacterial panel line it has developed NeoPlex RB-8.

GeneMatrix’s NeoPlex RV-Panel A is capable of collectively diagnosing 10 major respiratory viral pathogens, including influenza A/B, respiratory syncytial virus A/B, parainfluenza 1/2/3, and adenovirus, in a single test. Its NeoPlex RV-Panel B can simultaneously diagnose nine respiratory viruses, including coronavirus, enterovirus, and rhinovirus. GeneMatrix has completed the clinical trials of NeoPlex RV-Panel B which is ready for early market release.

Related Links:
GeneMatrix